



Syngene

Putting Science to Work

Discovery Services

Innovate

Integrate

Customize

Accelerate

30 years of Putting Science to Work



A Global CRO/CDMO

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small Molecules and Biologics, ADCs, Oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



Scientific Ecosystem

- 2.2 Mn sq. ft. world-class R&D and Manufacturing infrastructure
- Sites in Bangalore, Mangalore, and Hyderabad
- 6000+ qualified scientists including 550 PhDs
- Highly effective supply chain practices



IP Position

- IP assigned to clients
- Strong track record of Data Integrity and Security
- Over 400 patent assignments by clients recognizing Syngene



Marquee Clients

- 420+ active clients last FY
- Partnering with large / mid-size / emerging BioPharma (EBP) and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors



Quality Focus

- Quality driven organization
- Excellent track record of compliance with global regulators
- US FDA, EMA, ANVISA and PMDA approved, GLP Certified, Ministry of Health of Russian Federation, AAALAC & CAP accredited/certified facilities
- 15+ regulatory and 160+ client audits in the last 3 years



Track Record

- Collaborations and partnerships to deliver numerous clinical candidates
- Delivery history for integrated CMC programs towards FIH and beyond

Integrated Drug Discovery

Across multiple therapeutic areas and modalities to drive innovation and speed

Therapeutic Areas

- Oncology
- Immunology
- Neuroscience
- Infectious diseases
- Cardiovascular and metabolism
- Inflammation
- Rare/orphan diseases

Modalities

- Small molecules
- Peptides
- Oligonucleotides
- Antibodies
- Antibody drug conjugates
- PROTACs
- CAR-Ts

Drug discovery at a global scale

1600

scientists, with
95%+ Ms/Ph.D.

600,000

sq. ft. of
lab space

200+

global
clients







Efficiency through co-localization of team members and capabilities

- IDD programs for 8 clients over 6 therapeutic areas
- Syngene-Synvent for therapeutic discovery on behalf of clients
- High rate of repeat business and return-clients




Our Discovery Toolbox

We have the capabilities to apply the most appropriate modality for target validation and therapeutic discovery



Our End-to-End Discovery Platform

Our end-to-end platform allows us to offer integrated as well as standalone services across the discovery continuum



We deliver our services (both Integrated & Functional) via a range of proven collaboration models



Dedicated R&D Labs




FTE




FFS

Discovery Chemistry at Syngene

Discovery chemistry at Syngene is delivered by 900+ highly qualified scientists, backed by strong analytical chemistry support, robust IT infrastructure and ELN, as well as efficient data and compound management



Integrated & collaborative drug discovery
Seamless co-ordination between Chemistry, Biology, DMPK and animal studies



Analytical facilities supported by a team of 80 people
Strong IT support for ELN, data and compound management

Discovery Biology at Syngene

The Discovery Biology team supports drug discovery across multi-modal platforms including small and large molecules as well as cell and gene therapy, across multiple therapy areas. Our diverse team of scientists solve complex biological problems in an integrated fashion, embracing scientific excellence, operational efficiency and commercial competitiveness.



650+
scientists



110,000
sq. ft lab space
State of the art
infrastructure



Protein
Sciences



Cell
Engineering



Antibody Discovery
and engineering



Genomics and
translational



Assay Biology
& Screening



ADME DMPK



In Vivo
Pharmacology

Syngene Safety Assessment Services

Full range of *in vivo* and *in vitro* toxicology services for comprehensive non-clinical development of drugs

Exploratory studies	GLP studies	Phase I	Phase II	Phase III	Specialty studies
Pharmacokinetics	Analytical and bioanalytical studies to support safety tox program	Repeat dose studies & Genetic toxicology	Sub-chronic toxicity study		<i>In silico</i>
(MTD/Dose Escalation/Short-term repeat dose toxicology)	Repeat Dose Toxicology (2 Species)				Reproductive Toxicology (Male fertility/ Pre and Postnatal development)
Genotoxicity screening (<i>in vitro</i>)	Genotoxicity (<i>In vitro/ In vivo</i>)	Repeat dose studies & Genetic toxicology	Chronic Toxicology & Carcinogenicity		
Safety Pharmacology: CNS, Respiratory, CV	Toxicokinetics	Reproductive (Seg I-III) & Juvenile Toxicology			
	Core Battery Safety Pharmacology				
	Reproductive (Seg I-III) & Juvenile Toxicology				

Computational and Data Sciences Capabilities

Syngene's Computational and Data Sciences capabilities enable informed decisions at all stages of the drug discovery continuum



Target Identification and Validation



Hit Identification




Hit to Lead



Lead Optimization



Candidate Selection





Syngene
Putting Science to Work

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2024 Syngene International Limited, All Rights Reserved.

Stay Connected

